Reuters logo
AstraZeneca beats profit forecasts, helped by external deals
2015年7月30日 / 早上6点18分 / 2 年前

AstraZeneca beats profit forecasts, helped by external deals

LONDON, July 30 (Reuters) - AstraZeneca revenue fell by a smaller-than-expected 7 percent in the second quarter, as income from spinning off assets offset generic competition to older medicines and a strong dollar.

Quarterly sales totalled $6.3 billion, held back by cheap copycat versions of heartburn pill Nexium, while core earnings per share, which exclude certain items, fell 8 percent to $1.21 cents.

Industry analysts had on average forecast sales of $6.0 billion and earnings of $1.05 cents a share, according to Thomson Reuters. (Reporting by Ben Hirschler; editing by David Clarke)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below